Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
IKNL: verdubbeling patiënten met levercel- en galwegkanker
jan 2024 | Hepatologie, Maag-darm-leveroncologie